- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.08. | Nasdaq Stockholm AB: Change of Certified Adviser for Scandion Oncology A/S | 342 | GlobeNewswire | As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser
to Vator Securities AB.
This information is distributed at the request of the Certified Adviser, Västra
Hamnen Corporate... ► Artikel lesen | |
| 18.07. | Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 3 | 173 | GlobeNewswire | At the request of Scandion Oncology, Scandion Oncology equity rights will be
traded on First North Growth Market as from July 19, 2024.
Security name: Scandion Oncology TO 3
--------------------------------------
Short... ► Artikel lesen | |
| 18.07. | Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 2 | 190 | GlobeNewswire | At the request of Scandion Oncology, Scandion Oncology equity rights will be
traded on First North Growth Market as from July 19, 2024.
Security name: Scandion Oncology TO 2
--------------------------------------
Short... ► Artikel lesen | |
| 11.07. | Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Scandion Oncology | 368 | GlobeNewswire | At the request of Scandion Oncology, the last trading day in Scandion
Oncology's paid subscription units will be changed from 2024-07-11 to
2024-07-15.
Instrument: Paid subscription units... ► Artikel lesen | |
| 04.06. | Nasdaq Stockholm AB: Listing of subscription units and paid subscription units of Scandion Oncology | 359 | GlobeNewswire | With effect from June 05, 2024, the subscription units in Scandion Oncology
will be traded on First North Growth Market. Trading will continue up until and
including June 17, 2024.
Instrument:... ► Artikel lesen | |
| SCANDION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 31.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.05.2024 | 347 | Xetra Newsboard | Das Instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY wird ex Kapitalmassnahme gehandelt am 31.05.2024 The instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 23.05. | Scandion Oncology A/S: Scandion Oncology Announces The Final Terms Of The Rights Issue | 215 | GlobeNewswire (Europe) | On 19 April 2024, the board of directors of Scandion Oncology ("Scandion" or the "Company") resolved on the intention, subject to authorizations by the annual general meeting of the Company, to carry... ► Artikel lesen | |
| 22.05. | Scandion Oncology A/S: Scandion Oncology - Interim Report Q1 2024 | 120 | GlobeNewswire (Europe) | Scandion Oncology (Scandion) today announces its Interim Report Q1 2024. The following is taken from the report.
Francois Martelet, CEO:"Results from the CORIST Phase IIa trial have demonstrated impressive... ► Artikel lesen | |
| 13.05. | Scandion Oncology A/S: Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101 | 247 | GlobeNewswire (Europe) | Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, today announces final data from the PANTAX... ► Artikel lesen | |
| 28.02. | Scandion Oncology A/S: Scandion Oncology - Q4 & yearend report 2023 | 123 | GlobeNewswire (Europe) | Scandion Oncology (Scandion) today announces its Q4 & yearend report 2023. The following is taken from the report.
Francois Martelet, CEO:"Completion of and very positive topline results from part 3... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,220 | -0,39 % | Biotech Report: Evotec und Qiagen behauptet; US-Sektor legt zu | (shareribs.com) Frankfurt / New York 04.12.2024 - Biotech-Aktien zeigten sich im deutschen Handel überwiegend leichter. Unter anderem gaben 4SC und Vita34 nach. Für Evotec ging es leicht nach oben.... ► Artikel lesen | |
| DYNE THERAPEUTICS | 29,500 | +6,34 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,010 | +21,55 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,710 | +5,49 % | Beam Therapeutics Announces Positive Data From Phase 1/2 Trial Of BEAM-101 In Sickle Cell Disease | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease (SCD) with... ► Artikel lesen | |
| BIONTECH | 115,10 | -0,17 % | Erneut Klage gegen Biontech wegen Impfschäden abgewiesen | HAMBURG (dpa-AFX) - Das Landgericht Hamburg hat erneut eine Klage gegen den Corona-Impfstoffhersteller Biontech wegen möglicher Impfschäden abgewiesen. Die Klägerin habe nicht genügend ärztliche Unterlagen... ► Artikel lesen | |
| IMMUNOVANT | 28,620 | +0,77 % | Immunovant Inc.: Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 | Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease... ► Artikel lesen | |
| EVOTEC | 8,770 | -1,79 % | Evotec-Aktie: Das war nix! | Für einen Moment haben sich die Evotec-Aktionäre berechtigte Hoffnungen machen dürfen. Der Aktienkurs stieg für einige Wochen deutlich an und es sah kurz nach einem Ende der ewigen Abwärtsbewegung aus.... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 46,670 | +5,88 % | Kymera International erwirbt Coating Center Castrop GmbH | Research Triangle Park, North Carolina (ots/PRNewswire) - -- Kymera erweitert Präsenz seiner Sparte Oberflächentechnologien in Europa und erleichtert Kunden den Zugang zu fortschrittlichen Lösungen... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 69,85 | +2,52 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,460 | +0,73 % | PTA-News: Small- & MicroCap Investment: Die +440 %-Chance: NurExone mit dreistelligem Gewinn wie Vera Therapeutics oder Viking Therapeutics? | DJ PTA-News: Small- & MicroCap Investment: Die +440 %-Chance: NurExone mit dreistelligem Gewinn wie Vera Therapeutics oder Viking Therapeutics?
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| JANUX THERAPEUTICS | 64,75 | -2,34 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 19,090 | +6,95 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| NEUMORA THERAPEUTICS | 10,290 | +6,52 % | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,800 | +2,51 % | Looking Into ADMA Biologics' Recent Short Interest | ||
| PHATHOM PHARMACEUTICALS | 9,000 | +5,88 % | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter... ► Artikel lesen |
SCANDION ONCOLOGY A/S gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,007 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCANDION ONCOLOGY A/S finden Sie auf Wallstreet Online.
